Company intelligence / Profile preview
Vidasym
Chicago, Illinois, United Statesvidasym.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
VS-505 (phosphate binder) has completed a proof-of-concept clinical trial in hemodialysis patients showing efficacy with minimal side effects. VS-105 (vitamin D receptor agonist) has completed SAD/MAD studies in healthy subjects with good tolerability and no drug-related adverse events.
- Therapeutic areas
- GastroenterologyEndocrinologyDermatologyNephrology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
The China rights for VS-105 have been licensed out (partner not specified)
Beyond the preview
Go deeper on Vidasym.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vidasym.